Original Investigation


, Volume 191, Issue 4, pp 1023-1026

Aripiprazole in treatment of borderline patients, part II: an 18-month follow-up

  • Marius K. NickelAffiliated withClinic for Psychosomatic Medicine and Psychotherapy, Medical University of GrazUniversity Clinic for Psychiatry 1, PMU Email author 
  • , Thomas H. LoewAffiliated withDepartment of Psychosomatic Medicine, University Clinic
  • , Francisco Pedrosa GilAffiliated withPsychosomatic Outpatient Clinic, University Medicine Clinic, LMU

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



Only one controlled trial is known that employed aripiprazole for patients with borderline personality disorder (BPD). This 8-week trial found significant changes on most scales of the symptom checklist (SCL-90-R), Hamilton depression rating scale (HDRS), Hamilton anxiety rating scale (HARS), and on all scales of the state–trait anger expression inventory (STAXI).

Objectives, materials, and methods

To assess the long-term effectiveness of aripiprazole with multifaceted borderline symptomology, this 18-month follow-up observation with biannual testing was carried out with the same patients from the previous trial (treated with 15-mg aripiprazole daily, n = 26, 21 female and 5 male patients; previous placebo group, n = 26, 22 female and 4 male patients).


According to the intent-to-treat principle, significant changes on all scales of the SCL-90-R, HDRS, HARS, and STAXI were observed in the aripiprazole-treated subjects after 18 months.


Aripiprazole appears to be an effective and relatively safe agent in the long-term treatment of patients with BPD.


Borderline personality disorder Aripiprazole Hamilton depression rating scale